Synthetic hpGRF 1-40 stimulates growth hormone and inhibits prolactin secretion in normal children and children with isolated growth hormone deficiency.
Intravenously administered synthetic hpGRF 1-40 at doses of 0.1, 0.33 and 1.0 microgram/kg increased plasma GH in a dose-dependent fashion in 4 normal prepubertal children. hpGRF 1-40 at the dose of 1.0 microgram/kg stimulated GH release, though to a lesser extent than in normals, in 7 children with isolated GH-deficiency (IGHD) but failed to do so in a patient with craniopharyngioma. In all normal children and 6/7 patients with IGHD, hpGRF 1-40 at all doses used induced a clear and sustained lowering of plasma prolactin levels; this effect was lacking in the patient with craniopharyngioma. hpGRF 1-40 had no effect on plasma FSH, LH, TSH or glucose levels nor did it influence pulse rate, blood pressure, or body temperature. These results indicate that hpGRF 1-40 is a potent stimulus to GH release in normal prepubertal children and holds promise for treatment of GH-deficient children. In addition, in both normal children and children with IGHD, hpGRF 1-40 is a potent suppressor of prolactin levels.
D000293:Adolescent; D002648:Child; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000172:deficiency / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D007700:Kinetics; D008297:Male; D010446:Peptide Fragments; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D012016:Reference Values
D010446:Peptide Fragments; C036893:somatotropin releasing factor 40; D011388:Prolactin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone